Search clinical trials for: AZD1981

Total 183 results

AstraZeneca

Completed

Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers (ADME)

Healthy
AstraZeneca

Completed

14729-D9831C00002- 1 Month Biopsy Study (Biopsy)

Chronic Obstructive Pulmonary Disease

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids (OLIVE)

Asthma

Poland, Argentina, Brazil, Costa Rica
AstraZeneca

Completed

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)

Asthma Patients

United States, Mexico, Russian Federation, South Africa, Romania, Ukraine, Japan, Argentina, Slovakia, Brazil
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
AstraZeneca

Completed

Single and Multiple Ascending Doses of AZD1981 in Japan (JSAD/JMAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives

Oral Contraceptives

Sweden
AstraZeneca

Completed

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Healthy

Sweden
AstraZeneca

Completed

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

Healthy | Postmenopausal | Surgically Sterile Women

Sweden
Johns Hopkins University
AstraZeneca

Completed

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Chronic Idiopathic Urticaria

United States
AstraZeneca

Completed

Pharmacokinetics in Adolescents (PEAK)

Asthma

Sweden
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
AstraZeneca

Completed

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Pharmakokinetic

Sweden
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
AstraZeneca

Completed

Study of AZD8931 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Russian Federation, Germany
AstraZeneca

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Healthy

United Kingdom
AstraZeneca

Terminated

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Solid Malignancies

United States
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

Sensitivity in Esophagus

Denmark, Sweden
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (OA19)

Pain

Bulgaria, Poland, Hungary, Finland, Canada, Slovakia, Japan
AstraZeneca

Completed

Exploratory Study to Assess the Pharmacokinetics of AZD5985

Healthy

Germany
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386 (MAD)

Chronic Pain

United Kingdom
AstraZeneca

Terminated

AZD5985 Single Ascending Dose Study

Healthy

Sweden
AstraZeneca

Completed

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Healthy

United Kingdom
AstraZeneca

Completed

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

Healthy

United Kingdom
AstraZeneca

Completed

AZD1386 Japanese Multiple Ascending Dosing Study (JMAD)

Chronic Pain

Japan
AstraZeneca

Completed

To Investigate the Effects of AZD1981 on the QT Interval

Asthma

United Kingdom
Insmed Incorporated

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
AstraZeneca

Completed

Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

Pain

United Kingdom
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Healthy Volunteers

Pain | Esophageal Sensitivity

Sweden, Denmark
AstraZeneca

Completed

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Pharmacokinetics
AstraZeneca

Terminated

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

Pain | Neuropathic Pain

France, United Kingdom, Canada, Denmark
AstraZeneca

Terminated

Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment (CHIVE)

Breast Neoplasm

Korea, Republic of, Germany, Taiwan
AstraZeneca

Completed

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

Capsaicin Evoked Pain | Heat Sensitivity
Istituto Auxologico Italiano
University of Florence; Apnimed Inc.; VIS Ethic Research Srl; STM Pharma PRO srl

Recruiting

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome (ATOHS)

Obesity Hypoventilation Syndrome (OHS)

Italy
AstraZeneca

Completed

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Healthy Volunteers | Tolerability | Safety

United Kingdom
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
Imperial College London
AstraZeneca; Medical Research Council; National Institute for Health Research...

Completed

Neuropeptide Treatment for Hot Flushes During the Menopause (NK3R)

Menopausal Flushing

United Kingdom
AstraZeneca

Terminated

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Healthy Subjects

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Completed

A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin

Drug Interaction

Sweden
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
University of Washington
AstraZeneca

Terminated

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Completed

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States

Search clinical trials for: AZD1981

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations